腫瘍全体のRNAスプライシング異常は,行動可能な公開ネオアンチゲンを生成する
Darwin W Kwok1, Nicholas O Stevers1, Iñaki Etxeberria2,3
1Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Nature
|February 19, 2025
まとめ
科学者たちはRNAのスプライシングエラーから 新しい癌のネオアンチゲンを発見しました これらのネオアンチゲンはT細胞免疫療法によって標的となり,様々ながんの治療における課題を克服する可能性があります.
科学分野:
- 免疫学と腫瘍学
- 分子生物学
- ガンゲノミクス
背景:
- T細胞ベースの免疫療法は,がん特有の抗原を標的として,がん治療に希望を示しています.
- 効果はしばしば低体位変異率と腫瘍内における有意な異質性によって制限される.
研究 の 目的:
- RNA スプライシングの異常から生じる腫瘍全体の新種の公開ネオアンチゲンを特定し,特徴づけること.
- T細胞ベースのがん免疫療法におけるこれらのネオアンチゲンの可能性を評価する.
主な方法:
- 異常なRNAスプライシング (GNASとRPL22) からのネオアンチゲンを標的とするT細胞受容体クローンの識別.
- 多部位腫瘍生検の分析により,特定の新結合 (例えば,GNAS) の腫瘍全体の発現を確認する.
- ガン細胞に対する新抗原特異性CD8+T細胞応答の評価
主要な成果:
- RNA スプライシングの異常から得られた,以前は特徴づけられなかった腫瘍全体の新抗原の発見.
- GNASネオジャンクションが,膠原腫,中皮腫,前立腺癌,肝癌で腫瘍全体に発現することを示す.
- これらの内生的に生成されたネオアンチゲンが,CD8+T細胞による癌細胞の根絶を誘発することが確認された.
結論:
- 異常なRNAスプライシングは,T細胞によって認識される腫瘍全体の新抗原を生成する.
- 調節不良のスプライシングファクターの発現は,特定のがんにおける再発性ネオジャンクションアップレギュレーションに寄与する.
- これらの発見は,T細胞免疫療法の開発のための分子基盤を提供し, intratumoural heterogeneityに対処します.
関連する概念動画
RNA Splicing
55.9K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
55.9K
Alternative RNA Splicing
20.9K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
20.9K
Pre-mRNA Processing: RNA Splicing
5.2K
5.2K
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
Nonsense-mediated mRNA Decay
10.4K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
10.4K


